CRISPR Screening in Hepatocellular Carcinoma: From Tumor Progression to Immune Evasion and Therapeutic Resistance
Open Access
- 10 May 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4241
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advances in targeted therapies and immunotherapies, clinical outcomes remain poor owing to profound molecular heterogeneity, intrinsic therapeutic resistance, and complex immune evasion mechanisms. Although genomic profiling has identified recurrent alterations in HCC, large-scale functional validation of candidate drivers and vulnerabilities remains challenging. CRISPR (clustered regularly interspaced short palindromic repeats)-based screening technologies have transformed this landscape by enabling systematic interrogation of gene function in physiologically relevant contexts. In this review, we summarize recent studies that have applied CRISPR screening approaches in HCC research. These efforts have uncovered multilayered dependency programs that govern ferroptosis resistance, metabolic reprogramming, epigenetic regulation, tumor suppressor networks, immune evasion, and resistance to targeted therapies. We also discuss the major limitations of current studies, including model bias, incomplete representation of HCC heterogeneity, and technical constraints intrinsic to pooled screening. Overall, integration of CRISPR screening with patient-derived models, single-cell readouts, and precision editing technologies is expected to accelerate mechanistic discovery and biomarker-guided therapeutic prioritization for HCC.Keywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2023A1515140084)
- National Natural Science Foundation of China (32470673)
- the 111 Project (B16009)
- the Construction Project of Liaoning Provincial Key Laboratory, China (2022JH13/10200026)
This publication has 115 references indexed in Scilit:
- PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinomaCellular Oncology, 2025
- RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53 R249S Mutation and is a Potential Therapeutic TargetAdvanced Science, 2025
- COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular CarcinomaAdvanced Science, 2025
- High‐fidelity CRISPR/Cas12a dual‐crRNA screening reveals novel synergistic interactions in hepatocellular carcinomaClinical and Translational Medicine, 2024
- Stabilization of TGF‐β Receptor 1 by a Receptor‐Associated Adaptor Dictates Feedback Activation of the TGF‐β Signaling Pathway to Maintain Liver Cancer Stemness and Drug ResistanceAdvanced Science, 2024
- Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagyCancer Letters, 2023
- TUBB4B is a novel therapeutic target in non‐alcoholic fatty liver disease‐associated hepatocellular carcinomaThe Journal of Pathology, 2023
- Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome riskThe American Journal of Human Genetics, 2021
- Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classificationHepatology, 2018
- Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform†Hepatology, 2017